Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more
Chengdu Olymvax Biopharmaceuticals Inc. A (688319) - Net Assets
Latest net assets as of September 2025: CN¥968.34 Million CNY
Based on the latest financial reports, Chengdu Olymvax Biopharmaceuticals Inc. A (688319) has net assets worth CN¥968.34 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.94 Billion) and total liabilities (CN¥976.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥968.34 Million |
| % of Total Assets | 49.79% |
| Annual Growth Rate | 16.87% |
| 5-Year Change | 147.63% |
| 10-Year Change | 343.06% |
| Growth Volatility | 41.1 |
Chengdu Olymvax Biopharmaceuticals Inc. A - Net Assets Trend (2013–2024)
This chart illustrates how Chengdu Olymvax Biopharmaceuticals Inc. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chengdu Olymvax Biopharmaceuticals Inc. A (2013–2024)
The table below shows the annual net assets of Chengdu Olymvax Biopharmaceuticals Inc. A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥933.50 Million | +0.29% |
| 2023-12-31 | CN¥930.77 Million | +4.36% |
| 2022-12-31 | CN¥891.85 Million | +5.59% |
| 2021-12-31 | CN¥844.66 Million | +124.07% |
| 2020-12-31 | CN¥376.97 Million | +10.60% |
| 2019-12-31 | CN¥340.84 Million | +75.26% |
| 2018-12-31 | CN¥194.48 Million | -8.90% |
| 2017-12-31 | CN¥213.49 Million | +15.17% |
| 2016-12-31 | CN¥185.37 Million | -12.02% |
| 2015-12-31 | CN¥210.69 Million | +47.21% |
| 2014-12-31 | CN¥143.12 Million | -14.84% |
| 2013-12-31 | CN¥168.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Olymvax Biopharmaceuticals Inc. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4995078513.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥405.93 Million | 43.90% |
| Other Components | CN¥614.64 Million | 66.47% |
| Total Equity | CN¥924.68 Million | 100.00% |
Chengdu Olymvax Biopharmaceuticals Inc. A Competitors by Market Cap
The table below lists competitors of Chengdu Olymvax Biopharmaceuticals Inc. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
K.P.R. Mill Limited
NSE:KPRMILL
|
$1.06 Billion |
|
Shanghai Zijiang Enterprise Group Co Ltd
SHG:600210
|
$1.06 Billion |
|
alstria office REIT-AG
XETRA:AOX
|
$1.06 Billion |
|
Keli Sensing Technology Ningbo Co Ltd
SHG:603662
|
$1.06 Billion |
|
Mesoblast Limited
F:LWB
|
$1.06 Billion |
|
Sichuan Jiuzhou Electronic Co Ltd
SHE:000801
|
$1.06 Billion |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
$1.06 Billion |
|
GMéxico Transportes S.A.B. de C.V
PINK:GMXTF
|
$1.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Olymvax Biopharmaceuticals Inc. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 916,905,551 to 924,679,134, a change of 7,773,583 (0.8%).
- Net income of 20,757,588 contributed positively to equity growth.
- Dividend payments of 29,677,215 reduced retained earnings.
- Other factors increased equity by 16,693,210.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥20.76 Million | +2.24% |
| Dividends Paid | CN¥29.68 Million | -3.21% |
| Other Changes | CN¥16.69 Million | +1.81% |
| Total Change | CN¥- | 0.85% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Olymvax Biopharmaceuticals Inc. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.61x to 13.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.22 | CN¥31.31 | x |
| 2014-12-31 | CN¥1.04 | CN¥31.31 | x |
| 2015-12-31 | CN¥1.22 | CN¥31.31 | x |
| 2016-12-31 | CN¥0.94 | CN¥31.31 | x |
| 2017-12-31 | CN¥1.05 | CN¥31.31 | x |
| 2018-12-31 | CN¥0.95 | CN¥31.31 | x |
| 2019-12-31 | CN¥0.84 | CN¥31.31 | x |
| 2020-12-31 | CN¥0.93 | CN¥31.31 | x |
| 2021-12-31 | CN¥2.08 | CN¥31.31 | x |
| 2022-12-31 | CN¥2.18 | CN¥31.31 | x |
| 2023-12-31 | CN¥2.26 | CN¥31.31 | x |
| 2024-12-31 | CN¥2.28 | CN¥31.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Olymvax Biopharmaceuticals Inc. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.53%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.95x
- Recent ROE (2.24%) is above the historical average (-6.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -13.83% | -4664.27% | 0.00x | 1.36x | CN¥-40.04 Million |
| 2014 | -21.13% | -17770.40% | 0.00x | 1.49x | CN¥-44.55 Million |
| 2015 | -25.31% | -12485.61% | 0.00x | 1.28x | CN¥-73.04 Million |
| 2016 | -30.79% | -34430.80% | 0.00x | 1.13x | CN¥-73.56 Million |
| 2017 | 0.32% | 1.51% | 0.16x | 1.27x | CN¥-20.67 Million |
| 2018 | -9.77% | -24.90% | 0.27x | 1.45x | CN¥-38.45 Million |
| 2019 | -9.11% | -17.33% | 0.37x | 1.43x | CN¥-65.12 Million |
| 2020 | 9.58% | 11.29% | 0.50x | 1.70x | CN¥-1.57 Million |
| 2021 | 12.78% | 22.16% | 0.40x | 1.43x | CN¥23.50 Million |
| 2022 | 3.01% | 4.85% | 0.37x | 1.68x | CN¥-61.59 Million |
| 2023 | 1.91% | 3.54% | 0.31x | 1.76x | CN¥-74.13 Million |
| 2024 | 2.24% | 3.53% | 0.33x | 1.95x | CN¥-71.71 Million |
Industry Comparison
This section compares Chengdu Olymvax Biopharmaceuticals Inc. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals Inc. A (688319) | CN¥968.34 Million | -13.83% | 1.01x | $1.06 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |